Bevacizumab: off-label use in ophthalmology

Grisanti, Salvatore; Ziemssen, Focke
November 2007
Indian Journal of Ophthalmology;Nov2007, Vol. 55 Issue 6, p417
Academic Journal
journal article
Bevacizumab is a full-length, humanized monoclonal antibody directed against all the biologically active isoforms of vascular endothelial growth factor (VEGF-A). The antibody was initially designed and studied as an anti-angiogenic strategy to treat a variety of solid tumors. After approval by the US Food and Drug Administration, bevacizumab gained access into ophthalmology to treat various types of neovascular diseases. Since the first report in 2005 more than 100 publications share the experience with bevacizumab in ophthalmology. Two authors independently assessed the research results from Pubmed to April 2007. The reference list is a selection of key publications related to the issue. Currently, there is no well-designed randomized controlled trial yet to establish the efficacy and safety of intraocular bevacizumab for any ocular disease in spite of its assumed characteristics representing the most cost-effective VEGF inhibitor.


Related Articles

  • Bevacizumab ÖrneÄŸinde Türkiye'de Ruhsatli Endikasyon DiÅŸi DiÅŸi Ä°laç Kullaniminin Etik Yönden DeÄŸerlendirilmesi. Çakmak, Hasan Basri; Demır, Müge; Büken, Nükhet Örnek // Retina-Vitreus/Journal of Retina-Vitreous;Dec2008, Vol. 16 Issue 4, p311 

    Bevacizumab was used to inhibit neovascularisation as an systemic agent succesfully especialy in cancer treatment. Its use as an off-label drug in treatment of some ophthalmological diseases was increased in recent years. Off-label drug treatment can be described as use of a therapeutic agent...

  • Off-label bevacizumab shows promise for treating AMD. Charters, Lynda // Ophthalmology Times;2/1/2006, Vol. 31 Issue 3, p1 

    The article reports on discussions by physician Philip Rosenfeld on systemic and intravitreal use of bevacizumab at the American Academy of Ophthalmology Convention in 2006. Rosenfeld said that the off-label use of intravitreal bevacizumab, such as Genentech's Avastin, has the potential for...

  • Ocular inflammation outbreak seen in Canada. Webb, Jennifer A. // Ophthalmology Times;1/15/2009, Vol. 34 Issue 2, p1 

    The article reports that ophthalmologists in Canada hope that an ocular inflammation outbreak in patients treated with bevacizumab will not cause stricter regulations against it's off-label intravitreal use to treat wet age-related macular degeneration (AMD) in 2009. President of the Canadian...

  • Compounded interest. Webb, Jennifer A. // Ophthalmology Times;10/1/2011, Vol. 36 Issue 19, p1 

    The article focuses on the issue involving the reported cases of infections apparently linked to the off-label, intravitreal injections of bevacizumab in the U.S. The Department of Veterans Affairs (VA) states that they will reassess how the drug and other therapies may be made available for...

  • Prescrição Off-Label: Análise Científica tendo como Exemplo a Utilização de Bevacizumab em Oftalmologia. ALARCÃO, Joana; COSTA, João; FARELEIRA, Filipa; BORGES, Margarida; Vaz CARNEIRO, António // Acta Medica Portuguesa;Jul/Aug2013, Vol. 26 Issue 4, p409 

    Off-label prescribing poses specific technical/scientific, professional and ethical problems. In this study we carry out a technical and scientific analysis of the off-label prescribing using a current, clinical and economically relevant example: the paradigmatic case of the use of bevacizumab...

  • « OFF-LABEL » DRUG USE -- ETHICAL CHALLENGES. Branisteanu, Daniel Constantin; Munteanu, Mihnea; Branisteanu, Daciana Elena; Stanca, Horia Tudor; Moraru, Andreea; Balta, Florian // Revista Romana de Bioetica;Jul-Sep2015, Vol. 13 Issue 3, p83 

    « Off-label » administration of certain drugs has represented a common practice in medicine in the latest decades. Even if this attitude can be sanctioned with full responsibility transfer to the prescribing doctor, there is no law to punish this kind of practice if, from ethical point of...

  • Ophthalmology responds to bevacizumab embargo. Guttman, Cheryl // Ophthalmology Times;12/15/2007, Vol. 32 Issue 24, p1 

    The article presents information on the topics discussed at a meeting initiated by the American Academy of Ophthalmology (AAO). Attendees addressed concerns about the decision of Genentech Inc. to stop selling bevacizumab, used to fight cancer, to compounding pharmacies. AAO executive vice...

  • Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Kaiser, Peter; Cruess, Alan; Bogaert, Peter; Khunti, Kamlesh; Kelly, Simon // Graefe's Archive of Clinical & Experimental Ophthalmology;Nov2012, Vol. 250 Issue 11, p1563 

    Vascular endothelial growth factor (VEGF) inhibitor medications such as ranibizumab, pegaptanib and bevacizumab are in use for the treatment of neovascular age-related macular degeneration (AMD) and other retinal conditions, although only ranibizumab and pegaptanib are approved for these...

  • Bevacizumab.  // Reactions Weekly;Jun2015, Vol. 1555 Issue 1, p37 

    The article presents a case study of a 56-year old male patient, who developed haemorrhagic macular infarction following off-label use of bevacizumab.

  • Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration: What is the Evidence? Ziemssen, Focke; Grisanti, Salvatore; Bartz-Schmidt, Karl Ulrich; Spitzer, Martin S. // Drugs & Aging;2009, Vol. 26 Issue 4, p295 

    There is an active and controversial debate about the role of intravitreal bevacizumab versus approved drugs in the treatment of neovascular agerelated macular degeneration (AMD). Because bevacizumab was available prior to the launch of ranibizumab, off-label use of the former became widespread...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics